KING PHARMACEUTICALS (KG) Debt to Equity (2024 - 2026)
KING PHARMACEUTICALS (KG) debt to equity from Jun 30, 2024 to Mar 31, 2026. The current KING PHARMACEUTICALS (KG) debt to equity is 143.87%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Debt to Equity
Annual Debt to Equity change of KING PHARMACEUTICALS (KG)
| Year | Debt to Equity | Change |
|---|---|---|
| 2026 | 143.87% | +5.83% |
| 2025 | 135.95% | N/A |
| 2024 | 0.00% | N/A |
Comparison KING PHARMACEUTICALS (KG) debt to equity with competitors
KING PHARMACEUTICALS (KG) debt to equity is 143.87%.
| Ticker | Name | Debt to Equity | Upside |
|---|---|---|---|
| GLRE | Greenlight Capital Re Ltd - Class A | 0.64% | -99.56% |
| HG | Hamilton Insurance Group Ltd - Class B | 5.50% | -96.18% |
| RNR | RenaissanceRe Holdings Ltd | 20.24% | -85.93% |
| EG | Everest Group Ltd | 23.47% | -83.69% |
| SPNT | SiriusPoint Ltd | 29.52% | -79.48% |
| RGA | Reinsurance Group Of America Inc | 45.92% | -68.08% |